This page translates the Chinese website. Product availability and approved uses vary by country. Packaging and linked prescribing information may be in Chinese.
-
QLETLI?
adalimumab
Autoimmune
View Product
-
POBEVCY?
bevacizumab
Oncology
View Product
-
TOFIDENCE?
tocilizumab
Autoimmune
View Product
-
BETAGRIN?
bevifibatide citrate
Cardiovascular
View Product
-
STARJEMZA?USYMRO?
ustekinumab
Autoimmune
View Product
-
IMMGOLIS?/IMMGOLIS INTRI?GOTENFIA?
Golimumab
Autoimmune
View Product
-
BAT2306
Secukinumab Injection
Autoimmune
View Product
There are currently no matching products in this field.
QLETLI?
The First Adalimumab Biosimilar in Chinaadalimumab injection
Mechanism of action
Specifically binds to TNF-α and neutralizes its biological activity, blocking interaction with the cell-surface TNF-α receptors p55 and p75.
Specifications and packaging
QLETLI? adalimumab injection (20 mg/0.4 mL)
Disclaimer: The following products are prescription drugs and must be used under the guidance of a physician with experience in treating autoimmune diseases according to the instructions.
- Drug name
-
Generic Name adalimumab injection Brand Name QLETLI? English name Adalimumab Injection Chinese Pinyin Adamu Dankang Zhusheye
- Ingredients
- The principal ingredient is adalimumab.
- Specifications
- 20 mg/0.4 mL; one prefilled syringe per carton; subcutaneous injection
- Description
- This product is a clear liquid prefilled in a syringe
- Indications
-
- Crohn's disease in children
- plaque psoriasis in children
- polyarticular juvenile idiopathic arthritis
- Chinese Approval No.
- Chinese Approval No. S20217001
Refer to the prescribing information for dosage and administration, adverse reactions, contraindications, precautions and other details.
Medical consultation hotline:400-999-8703
QLETLI? adalimumab injection (40 mg/0.8 mL)
Disclaimer: The following products are prescription drugs and must be used under the guidance of a physician with experience in treating autoimmune diseases according to the instructions.
- Drug name
-
Generic Name adalimumab injection Brand Name QLETLI? English name Adalimumab Injection Chinese Pinyin Adamu Dankang Zhusheye
- Ingredients
- The principal ingredient is adalimumab.
- Specifications
- 40 mg/0.8 mL; one prefilled syringe per carton; subcutaneous injection
- Description
- This product is a clear liquid prefilled in a syringe
- Indications
-
- rheumatoid arthritis
- ankylosing spondylitis
- psoriasis
- Crohn's disease
- uveitis
- Crohn's disease in children
- plaque psoriasis in children
- polyarticular juvenile idiopathic arthritis
- Chinese Approval No.
- Chinese Approval No. S20190038
Refer to the prescribing information for dosage and administration, adverse reactions, contraindications, precautions and other details.
Medical consultation hotline:400-999-8703
POBEVCY?
bevacizumab injection · Avzivi? / Bevyx?
Mechanism of action
Binds to human vascular endothelial growth factor (VEGF), inhibiting its interaction with its receptors and blocking angiogenesis signaling.
Specifications and packaging
POBEVCY? bevacizumab injection (100 mg/4 mL)
Disclaimer: The following products are prescription drugs and must be used under the guidance of a physician with relevant treatment experience according to the instructions and prescriptions.
- Drug name
-
Generic Name bevacizumab injection Brand Name POBEVCY? English name Bevacizumab Injection Chinese Pinyin Beifazhu Dankang Zhusheye
- Ingredients
- The principal ingredient is bevacizumab.
- Specifications
- 100 mg/4 mL; one vial per carton; intravenous injection
- Description
- This product is a sterile solution for intravenous injection, pH 5.9-6.3, clear to slightly opalescent, colorless to light brown liquid
- Indications
-
- metastatic colorectal cancer
- Advanced, metastatic or recurrent non-small cell lung cancer
- cervical cancer
- recurrent glioblastoma
- Epithelial ovarian, fallopian tube, or primary peritoneal cancer
- hepatocellular carcinoma
- Chinese Approval No.
- Chinese Approval No. S20210044
Refer to the prescribing information for dosage and administration, adverse reactions, contraindications, precautions and other details.
Medical consultation hotline:400-999-8703
POBEVCY? bevacizumab injection (400 mg/16 mL)
Disclaimer: The following products are prescription drugs and must be used under the guidance of a physician with relevant treatment experience according to the instructions and prescriptions.
- Drug name
-
Generic Name bevacizumab injection Brand Name POBEVCY? English name Bevacizumab Injection Chinese Pinyin Beifazhu Dankang Zhusheye
- Ingredients
- The principal ingredient is bevacizumab.
- Specifications
- 400 mg/16 mL; one vial per carton; intravenous injection
- Description
- This product is a sterile solution for intravenous injection, pH 5.9-6.3, clear to slightly opalescent, colorless to light brown liquid
- Indications
-
- metastatic colorectal cancer
- Advanced, metastatic or recurrent non-small cell lung cancer
- cervical cancer
- recurrent glioblastoma
- Epithelial ovarian, fallopian tube, or primary peritoneal cancer
- hepatocellular carcinoma
- Chinese Approval No.
- Chinese Approval No. S20210045
Refer to the prescribing information for dosage and administration, adverse reactions, contraindications, precautions and other details.
Medical consultation hotline:400-999-8703
TOFIDENCE?
The World’s First Tocilizumab Biosimilartocilizumab injection
Mechanism of action
Targets the interleukin-6 receptor (IL-6R), specifically binding to soluble and membrane-bound receptors (sIL-6R and mIL-6R) and inhibiting the signaling they mediate.
Specifications and packaging
TOFIDENCE? tocilizumab injection (80 mg/4 mL)
Disclaimer: The following products are prescription drugs and must be used under the guidance of medical and pharmaceutical professionals with reference to the instructions and prescriptions.
- Drug name
-
Generic Name tocilizumab injection Brand Name TOFIDENCE? English name Tocilizumab Injection Chinese Pinyin Tuozhu Dankang Zhusheye
- Ingredients
- The principal ingredient is tocilizumab.
- Specifications
- 80 mg/4 mL; 1 or 4 vials per carton; intravenous infusion
- Description
- This product is colorless to light yellow clear liquid with slight opalescence.
- Indications
-
- rheumatoid arthritis
- systemic juvenile idiopathic arthritis
- cytokine release syndrome
- Chinese Approval No.
- Chinese Approval No. S20230003
Refer to the prescribing information for dosage and administration, adverse reactions, contraindications, precautions and other details.
Medical consultation hotline:400-999-8703
TOFIDENCE? tocilizumab injection (200 mg/10 mL)
Disclaimer: The following products are prescription drugs and must be used under the guidance of medical and pharmaceutical professionals with reference to the instructions and prescriptions.
- Drug name
-
Generic Name tocilizumab injection Brand Name TOFIDENCE? English name Tocilizumab Injection Chinese Pinyin Tuozhu Dankang Zhusheye
- Ingredients
- The principal ingredient is tocilizumab.
- Specifications
- 200 mg/10 mL; 1 or 4 vials per carton; intravenous infusion
- Description
- This product is colorless to light yellow clear liquid with slight opalescence.
- Indications
-
- rheumatoid arthritis
- systemic juvenile idiopathic arthritis
- cytokine release syndrome
- Chinese Approval No.
- Chinese Approval No. S20240009
Refer to the prescribing information for dosage and administration, adverse reactions, contraindications, precautions and other details.
Medical consultation hotline:400-999-8703
TOFIDENCE? tocilizumab injection (400 mg/20 mL)
Disclaimer: The following products are prescription drugs and must be used under the guidance of medical and pharmaceutical professionals with reference to the instructions and prescriptions.
- Drug name
-
Generic Name tocilizumab injection Brand Name TOFIDENCE? English name Tocilizumab Injection Chinese Pinyin Tuozhu Dankang Zhusheye
- Ingredients
- The principal ingredient is tocilizumab.
- Specifications
- 400 mg/20 mL; 1 or 4 vials per carton; intravenous infusion
- Description
- This product is colorless to light yellow clear liquid with slight opalescence.
- Indications
-
- rheumatoid arthritis
- systemic juvenile idiopathic arthritis
- cytokine release syndrome
- Chinese Approval No.
- Chinese Approval No. S20230001
Refer to the prescribing information for dosage and administration, adverse reactions, contraindications, precautions and other details.
Medical consultation hotline:400-999-8703
BETAGRIN?
China Class 1 Innovative Drugbevifibatide citrate injection
Mechanism of action
A peptide β3 integrin receptor inhibitor that targets both the platelet glycoprotein receptor αIIbβ3 (also known as IIb/IIIa) and the integrin receptor αvβ3.
Specifications and packaging
BETAGRIN? bevifibatide citrate injection (20 mg/10 mL)
Disclaimer: The following products are all prescription drugs and must be used under the guidance of a physician with experience in treating cardiovascular disease according to the instructions.
- Drug name
-
Generic Name bevifibatide citrate injection Brand Name BETAGRIN? English name Bevifibatide Citrate Injection Chinese Pinyin Juyuansuan Beiweibatai Zhusheye
- Ingredients
- The principal active ingredient is bevifibatide citrate.
- Specifications
- 20 mg/10 mL, intravenously
- Description
- This product is colorless clear liquid
- Indications
-
- For use in patients with acute coronary syndrome undergoing percutaneous coronary intervention, including intracoronary stent placement, to reduce the risk of acute occlusion, stent thrombosis, no-reflow, and slow flow
- Chinese Approval No.
- Chinese Approval No. H20240030
Refer to the prescribing information for dosage and administration, adverse reactions, contraindications, precautions and other details.
Medical consultation hotline:400-999-8703
STARJEMZA?USYMRO?
ustekinumab injection · STARJEMZA? / USYMRO?
Mechanism of action
—
Specifications and packaging
STARJEMZA?USYMRO? ustekinumab injection (45 mg/0.5 mL)
Disclaimer: The following products are prescription drugs and must be used under the guidance of a physician with experience in treating autoimmune diseases according to the instructions.
- Drug name
-
Generic Name ustekinumab injection Brand Name STARJEMZA?USYMRO? English name Ustekinumab Injection Chinese Pinyin Wusinu Dankang Zhusheye
- Ingredients
- The principal ingredient is ustekinumab.
- Specifications
- 45 mg/0.5 mL; one prefilled syringe per carton; subcutaneous injection
- Description
- This product is a colorless to light yellow clear solution prefilled in a syringe
- Indications
-
- Adult plaque psoriasis
- Crohn's disease
- plaque psoriasis in children
- Chinese Approval No.
- Chinese Approval No. S20260031
Refer to the prescribing information for dosage and administration, adverse reactions, contraindications, precautions and other details.
Medical consultation hotline:400-999-8703
STARJEMZA?USYMRO? ustekinumab injection (90 mg/mL)
Disclaimer: The following products are prescription drugs and must be used under the guidance of a physician with experience in treating autoimmune diseases according to the instructions.
- Drug name
-
Generic Name ustekinumab injection Brand Name STARJEMZA?USYMRO? English name Ustekinumab Injection Chinese Pinyin Wusinu Dankang Zhusheye
- Ingredients
- The principal ingredient is ustekinumab.
- Specifications
- 90 mg/mL; one prefilled syringe per carton; subcutaneous injection
- Description
- This product is a colorless to light yellow clear solution prefilled in a syringe
- Indications
-
- Adult plaque psoriasis
- Crohn's disease
- plaque psoriasis in children
- Chinese Approval No.
- Chinese Approval No. S20260030
Refer to the prescribing information for dosage and administration, adverse reactions, contraindications, precautions and other details.
Medical consultation hotline:400-999-8703
STARJEMZA?USYMRO? ustekinumab injection (intravenous infusion · 130 mg/26 mL)
Disclaimer: The following products are prescription drugs and must be used under the guidance of a physician with experience in treating autoimmune diseases according to the instructions.
- Drug name
-
Generic Name ustekinumab injection Brand Name STARJEMZA?USYMRO? English name Ustekinumab Injection (Intravenous Infusion) Chinese Pinyin Wusinu Dankang Zhusheye
- Ingredients
- The principal ingredient is ustekinumab.
- Specifications
- 130 mg/26 mL; one vial per carton; intravenous infusion
- Description
- This product is a sterile solution for intravenous infusion
- Indications
-
- Crohn's disease
- Chinese Approval No.
- Chinese Approval No. S20260027
Refer to the prescribing information for dosage and administration, adverse reactions, contraindications, precautions and other details.
Medical consultation hotline:400-999-8703
IMMGOLIS?/IMMGOLIS INTRI?GOTENFIA?
First golimumab biosimilar in Chinagolimumab injection
Mechanism of action
Golimumab is an antibody targeting TNF-α that can specifically bind with high affinity to both soluble and transmembrane human TNF-α, blocking the binding of TNF-α to its receptor TNFR, thereby inhibiting the activity of TNF-α.
Specifications and packaging
golimumab injection (50 mg/0.5 mL)
Disclaimer: The following products are prescription drugs and must be used under the guidance of a physician with experience in treating autoimmune diseases according to the instructions.
- Drug name
-
Generic Name golimumab injection Brand Name IMMGOLIS?/IMMGOLIS INTRI?GOTENFIA? English name Golimumab Injection Chinese Pinyin Gelimu Dankang Zhusheye
- Ingredients
- The principal ingredient is golimumab.
- Specifications
- 50 mg/0.5 mL/tube/box, subcutaneous injection
- Description
- This product is a colorless to light yellow clear solution prefilled in a syringe
- Indications
-
- rheumatoid arthritis
- ankylosing spondylitis
- Chinese Approval No.
- Chinese Approval No. S20260080
Refer to the prescribing information for dosage and administration, adverse reactions, contraindications, precautions and other details.
Medical consultation hotline:400-999-8703
golimumab injection (100 mg/mL)
Disclaimer: The following products are prescription drugs and must be used under the guidance of a physician with experience in treating autoimmune diseases according to the instructions.
- Drug name
-
Generic Name golimumab injection Brand Name IMMGOLIS?/GOTENFIA? English name Golimumab Injection Chinese Pinyin Gelimu Dankang Zhusheye
- Ingredients
- The principal ingredient is golimumab.
- Specifications
- 100 mg/mL/tube/box, subcutaneous injection
- Description
- This product is a colorless to light yellow clear solution prefilled in a syringe
- Indications
-
- rheumatoid arthritis
- ulcerative colitis
- Chinese Approval No.
- It has been approved in Europe and the United States
Refer to the prescribing information for dosage and administration, adverse reactions, contraindications, precautions and other details.
Medical consultation hotline:400-999-8703
golimumab injection (50 mg/4 mL)
Disclaimer: The following products are prescription drugs and must be used under the guidance of a physician with experience in treating autoimmune diseases according to the instructions.
- Drug name
-
Generic Name golimumab injection Brand Name IMMGOLIS INTRI? English name Golimumab Injection Chinese Pinyin Gelimu Dankang Zhusheye
- Ingredients
- The principal ingredient is golimumab.
- Specifications
- 50 mg/4 mL/bottle/box, intravenous infusion
- Description
- This product is a sterile solution for intravenous infusion
- Indications
-
- rheumatoid arthritis
- Chinese Approval No.
- It has been approved for marketing in the United States, but has not yet been approved for marketing in China.
Refer to the prescribing information for dosage and administration, adverse reactions, contraindications, precautions and other details.
Medical consultation hotline:400-999-8703
BAT2306
First approved secukinumab biosimilar globallySecukinumab Injection
Mechanism of action
BAT2306 is an anti-human interleukin-17A (IL-17A) monoclonal antibody (IgG1κ) that selectively binds to IL-17A to inhibit its interaction with the IL-17 receptor, thereby suppressing the release of pro-inflammatory cytokines and chemokines. IL-17A is a cytokine produced during human inflammatory and immune responses and plays an important role in the pathogenesis of multiple autoimmune diseases. Increased numbers of IL-17A-secreting lymphocytes and elevated IL-17A levels have been found in the blood of patients with psoriasis, psoriatic arthritis, and ankylosing spondylitis.
Specifications and packaging
BAT2306 Secukinumab Injection75mg（0.5ml）
Disclaimer: The following products are prescription drugs and must be used under the guidance of a physician with relevant treatment experience according to the instructions and prescriptions.
- Drug name
-
Generic Name Scukinumab Injection Brand Name BAT2306 English name Scukinumab Injection Chinese Pinyin Sikuqiyou Dankang Zhusheye
- Ingredients
- The main ingredient is scukinumab.
- Specifications
- 75mg（0.5ml）; subcutaneous injection
- Description
- Colorless to pale yellow liquid
- Indications
-
- Plaque psoriasis,
- Psoriatic arthritis,
- Ankylosing spondylitis
- Chinese Approval No.
- NMPA Approval No. S20260076
Refer to the prescribing information for dosage and administration, adverse reactions, contraindications, precautions and other details.
Medical consultation hotline:400-999-8703
BAT2306 Secukinumab Injection75mg（0.5ml）
Disclaimer: The following products are prescription drugs and must be used under the guidance of a physician with relevant treatment experience according to the instructions and prescriptions.
- Drug name
-
Generic Name Scukinumab Injection Brand Name BAT2306 English name Scukinumab Injection Chinese Pinyin Sikuqiyou Dankang Zhusheye
- Ingredients
- The main ingredient is scukinumab.
- Specifications
- 150mg（1ml）; subcutaneous injection
- Description
- Colorless to pale yellow liquid
- Indications
-
- Plaque psoriasis,
- Psoriatic arthritis,
- Ankylosing spondylitis
- Chinese Approval No.
- NMPA Approval No. S20260077
Refer to the prescribing information for dosage and administration, adverse reactions, contraindications, precautions and other details.
Medical consultation hotline:400-999-8703
More candidate drugs under development can be found in the R&D pipeline; for business cooperation and supply, please contact the business team.
+ View R&D pipeline